JP2020521767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521767A5 JP2020521767A5 JP2019565399A JP2019565399A JP2020521767A5 JP 2020521767 A5 JP2020521767 A5 JP 2020521767A5 JP 2019565399 A JP2019565399 A JP 2019565399A JP 2019565399 A JP2019565399 A JP 2019565399A JP 2020521767 A5 JP2020521767 A5 JP 2020521767A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- solvate
- pharmaceutically acceptable
- hydrate
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 150000001204 N-oxides Chemical class 0.000 claims 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- -1 C 1-6 alkyl-OH Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000008795 neuromyelitis optica Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000016686 tic disease Diseases 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510223P | 2017-05-23 | 2017-05-23 | |
| US62/510,223 | 2017-05-23 | ||
| PCT/US2018/033964 WO2018217809A1 (en) | 2017-05-23 | 2018-05-22 | Pyrazole magl inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020521767A JP2020521767A (ja) | 2020-07-27 |
| JP2020521767A5 true JP2020521767A5 (enExample) | 2021-07-26 |
| JPWO2018217809A5 JPWO2018217809A5 (enExample) | 2022-07-26 |
| JP7162622B2 JP7162622B2 (ja) | 2022-10-28 |
Family
ID=64397012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565399A Active JP7162622B2 (ja) | 2017-05-23 | 2018-05-22 | ピラゾールｍａｇｌ阻害剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11149037B2 (enExample) |
| EP (1) | EP3634404B1 (enExample) |
| JP (1) | JP7162622B2 (enExample) |
| KR (1) | KR20200010366A (enExample) |
| CN (1) | CN110678177B (enExample) |
| AU (1) | AU2018273888A1 (enExample) |
| BR (1) | BR112019024488A2 (enExample) |
| CA (1) | CA3065898A1 (enExample) |
| CL (1) | CL2019003398A1 (enExample) |
| CO (1) | CO2019013016A2 (enExample) |
| CR (1) | CR20190537A (enExample) |
| DO (1) | DOP2019000295A (enExample) |
| EA (1) | EA201992504A1 (enExample) |
| EC (1) | ECSP19083923A (enExample) |
| ES (1) | ES3005265T3 (enExample) |
| JO (1) | JOP20190267A1 (enExample) |
| MA (1) | MA50405A (enExample) |
| MX (1) | MX2019014041A (enExample) |
| NI (1) | NI201900120A (enExample) |
| PE (1) | PE20200293A1 (enExample) |
| PH (1) | PH12019502646A1 (enExample) |
| RU (1) | RU2019137094A (enExample) |
| WO (1) | WO2018217809A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| US10583137B2 (en) | 2015-12-02 | 2020-03-10 | The Scripps Research Institute | Triazole DAGLα inhibitors |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| LT3630744T (lt) | 2017-05-23 | 2023-03-10 | H. Lundbeck A/S | Pirazolo magl inhibitoriai |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
| CN114096545A (zh) * | 2019-07-09 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 新杂环化合物 |
| WO2022057928A1 (zh) * | 2020-09-18 | 2022-03-24 | 上海医药集团股份有限公司 | 一种羰基杂环类化合物及其应用 |
| US20240174680A1 (en) | 2021-01-29 | 2024-05-30 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| US12053459B2 (en) | 2021-06-26 | 2024-08-06 | Cedilla Therapeutics, Inc. | CDK2 inhibitors and methods of using the same |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
| WO2025221154A1 (en) | 2024-04-17 | 2025-10-23 | Captor Therapeutics S.A. | Klhdc2 (kelch domain-containing protein 2) ligase ligands |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3308130A (en) | 1962-04-26 | 1967-03-07 | Du Pont | N-disubstituted carbamyl pyrazoles |
| EP1309591B1 (en) | 2000-08-14 | 2007-01-24 | Ortho-McNeil Pharmaceutical, Inc. | Substituted pyrazoles |
| US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| MXPA04007995A (es) * | 2002-02-19 | 2004-11-26 | Teva Pharma | Desolvatacion de solvatos de hemicalcio de atorvastatina. |
| SE0300705D0 (sv) | 2003-03-14 | 2003-03-14 | Biolipox Ab | New compounds |
| CA2665804A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| TWI469979B (zh) | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| US9108930B2 (en) | 2011-04-06 | 2015-08-18 | The Scripps Research Institute | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| US9624170B2 (en) | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| BR112017001353B1 (pt) * | 2014-07-23 | 2022-02-22 | Baker Hughes Incorporated | Aparelho e método para monitorar escala orgânica de fundo de poço e intervir em um poço de produção |
| US10570146B2 (en) | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| WO2017087863A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN108601769B (zh) * | 2015-11-20 | 2021-09-03 | H.隆德贝克有限公司 | 吡唑化合物及其制备和使用方法 |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| US10583137B2 (en) | 2015-12-02 | 2020-03-10 | The Scripps Research Institute | Triazole DAGLα inhibitors |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| LT3630744T (lt) | 2017-05-23 | 2023-03-10 | H. Lundbeck A/S | Pirazolo magl inhibitoriai |
-
2017
- 2017-06-16 JO JOP/2019/0267A patent/JOP20190267A1/ar unknown
-
2018
- 2018-05-22 US US16/615,746 patent/US11149037B2/en active Active
- 2018-05-22 CA CA3065898A patent/CA3065898A1/en not_active Abandoned
- 2018-05-22 MA MA050405A patent/MA50405A/fr unknown
- 2018-05-22 PE PE2019002453A patent/PE20200293A1/es unknown
- 2018-05-22 AU AU2018273888A patent/AU2018273888A1/en not_active Abandoned
- 2018-05-22 EA EA201992504A patent/EA201992504A1/ru unknown
- 2018-05-22 MX MX2019014041A patent/MX2019014041A/es unknown
- 2018-05-22 BR BR112019024488-3A patent/BR112019024488A2/pt not_active Application Discontinuation
- 2018-05-22 WO PCT/US2018/033964 patent/WO2018217809A1/en not_active Ceased
- 2018-05-22 CN CN201880033866.9A patent/CN110678177B/zh active Active
- 2018-05-22 EP EP18805515.6A patent/EP3634404B1/en active Active
- 2018-05-22 KR KR1020197037406A patent/KR20200010366A/ko not_active Withdrawn
- 2018-05-22 RU RU2019137094A patent/RU2019137094A/ru not_active Application Discontinuation
- 2018-05-22 JP JP2019565399A patent/JP7162622B2/ja active Active
- 2018-05-22 CR CR20190537A patent/CR20190537A/es unknown
- 2018-05-22 ES ES18805515T patent/ES3005265T3/es active Active
-
2019
- 2019-11-20 DO DO2019000295A patent/DOP2019000295A/es unknown
- 2019-11-21 CO CONC2019/0013016A patent/CO2019013016A2/es unknown
- 2019-11-21 CL CL2019003398A patent/CL2019003398A1/es unknown
- 2019-11-22 NI NI201900120A patent/NI201900120A/es unknown
- 2019-11-22 PH PH12019502646A patent/PH12019502646A1/en unknown
- 2019-11-25 EC ECSENADI201983923A patent/ECSP19083923A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521767A5 (enExample) | ||
| JP2020521766A5 (enExample) | ||
| RU2019137094A (ru) | Ингибиторы magl на основе пиразола | |
| JP2018526399A5 (enExample) | ||
| CN115427414A (zh) | 稠环化合物及其在医药上的应用 | |
| CN113614080A (zh) | Kras g12c抑制剂化合物及其用途 | |
| JP2020507582A5 (enExample) | ||
| MX2020005874A (es) | Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa). | |
| JP2020521740A5 (enExample) | ||
| JP2010524899A5 (enExample) | ||
| JPWO2019013311A5 (enExample) | ||
| JP2010509284A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2014506599A5 (enExample) | ||
| JP2016504378A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2017518959A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| JP2010509285A5 (enExample) | ||
| JP2019537603A5 (enExample) |